To characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation. Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug cessation. Is hypoglycemia related to use of plaquenil Ashwagandha and plaquenil When do you use hydroxychloroquine in rheumatoid arthritis Plaquenil and sulfasalazine Nov 01, 2015 SHIRI SHULMAN, MD. H ydroxychloroquine HCQ; Plaquenil, Sanofi, Bridgewater, NJ is an antimalarial agent that is also commonly used as a treatment for a variety of rheumatologic and dermatologic conditions, such as rheumatoid arthritis and systemic lupus erythematosus. The most common side effect associated with its use is retinal toxicity. Objectives. This study aims to detect hydroxychloroquine HCQ-induced retinal toxicity at an earlier stage through the use of spectral-domain optical coherence tomography device, especially by measuring macular retinal ganglion cell-inner plexiform layer RGC-IPL thickness. Hydroxychloroquine, sold under the brand name Plaquenil Sanofi-Aventis, is an antimalarial drug that has gained widespread use in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. 1 By some estimates, more than 150,000 patients are on long-term therapy with this medication in America alone. 2 Retinal toxicity associated with HCQ use is. Main Outcome Measures: SD-OCT findings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Retrospective clinical data review by the Boston Image Reading Center. Plaquenil toxicity macular oct Plaquenil Toxicity - Retina Image Bank, A New Objective Parameter in Hydroxychloroquine-Induced. Hydroxychloroquine hypoglycemiaWhat is chloroquine phosphate Although hydroxychloroquine retinal toxicity is thought to be rare, recent studies suggest it may have a higher prevalence than previously recognized. A large study examining patients with more than 5 years of HCQ use were evaluated with 10-2 visual fields or spectral-domain optical coherence tomography SD OCT. Hydroxychloroquine Plaquenil Toxicity and.. Multimodal Imaging in Plaquenil Toxicity. Early Plaquenil Toxicity Detected without Bull’s Eye.. Hence, it is imperative that we become familiar with recognizing the spectrum of HVF and SD-OCT findings associated with Plaquenil retinal toxicity. Of note, SD-OCT, in combination with Humphrey visual field testing, is critical for the early detection of Plaquenil retinal toxicity. Lyons emphasizes the importance of annual screening and says that, although annual screening is recommended for everyone taking Plaquenil, it is imperative for people who have been taking the medication for more than 10 years, who have a higher incidence of retinal toxicity. Plaquenil-induced toxicity usually will not occur before five years of. Hydroxychloroquine HCQ has been used for therapy of rheumatologic disorders since the 1950s. Ocular toxicity associated with HCQ use was initially described in the 1960s 1, 2incidence of HCQ retinopathy is estimated at 1 % after consumption of HCQ for 5 years is marked by paracentral and central scotoma and decreased color vision.